Loading organizations...
§ Private Profile · Tokyo, Tokyo, Japan
Biotech startup developing next-generation oral anticancer drugs that induce ferroptosis for cancer patients, focused on oncology.
Founded in May 2022 by CEO Yuji Otsuki and four fellow researchers as a Keio University spin-off, FerroptoCure is a biotechnology startup based in Chiyoda-ku, Tokyo. The early clinical stage firm develops next-generation oral anticancer drugs that induce ferroptosis, a regulated cell death driven by oxidative stress, to treat triple-negative breast cancer alongside skin and musculoskeletal diseases. Its board features notable academic experts, including Hideyuki Saya, Osamu Nagano, Nobuhiro Nishiyama, and Toru Natsume, who guide the company through its Phase 1 drug pipelines. Operating with fewer than ten employees, the enterprise recently completed a $3.0 million Series A funding round to support its ongoing research and development operations. This venture capital investment builds upon a previous $4.0 million seed fundraising target, ensuring the startup can continue advancing accessible oncology treatments for patients with unmet medical needs.
FerroptoCure has raised $6.5M across 1 funding round.
FerroptoCure has raised $6.5M in total across 1 funding round.
FerroptoCure has raised $6.5M across 1 funding round. Most recently, it raised $6.5M Grant / Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 19, 2025 | $6.5M Grant | — | Kazuhiro Sakakibara, Terumitsu Hasebe, Japanese Agency For Medical Research And Development, Japan Science And Technology Agency, Yuichi Katayo, Kunio Matsumoto | Announced |
FerroptoCure has raised $6.5M in total across 1 funding round.
FerroptoCure's investors include Kazuhiro Sakakibara, Terumitsu Hasebe, Japanese Agency for Medical Research and Development, Japan Science and Technology Agency, Yuichi Katayo, Kunio Matsumoto.